HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock PR Newswire FRAMINGHAM, Mass. and SYDNEY, March 12, 2013 FRAMINGHAM, Mass. and SYDNEY, March 12, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the pricing of a public offering of 1,500,000 shares of common stock at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC"). HeartWare also granted the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments, if any. HeartWare intends to use the net proceeds from the offering for working capital and general corporate purposes, including, but not limited to, research and development, expansion of manufacturing capabilities, selling and marketing activities, capital investments in information systems, facilities and infrastructure, and general and administrative support functions to support growth and the acquisition or licensing of or investment in complementary products, technologies or businesses. J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. Canaccord Genuity Inc., Credit Suisse Securities (USA) LLC and Lazard Capital Markets LLC are acting as co-managers of the offering. Perella Weinberg Partners served as independent capital markets advisor to HeartWare on this offering. The offering does not require the prior approval of HeartWare's stockholders under the requirements of the Australian Stock Exchange. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. The offering will be made only by means of a prospectus and the related prospectus supplement. Before you invest, you should read the prospectus and the related prospectus supplement and any other document HeartWare has filed with the SEC for more complete information about HeartWare and the offering. You may get these documents for free by visiting EDGAR on the SEC Website at www.sec.gov. Alternatively, copies of the prospectus and the related prospectus supplement can be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by calling 1-866-803-9204. About HeartWare International HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. Forward-Looking Statements This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the commercial launch of the HeartWare^® Ventricular Assist System in the U.S., continued support from international customers, progress of clinical trials and post-approval studies, regulatory status, research and development activities, commercialization strategies and the use of proceeds from this offering. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation those described in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission. We may update our risk factors from time to time in Part II, Item 1A "Risk Factors" in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the Securities and Exchange Commission. For further information: Christopher Taylor HeartWare International, Inc. Email: email@example.com Phone: +1 508 739 0864 SOURCE HeartWare International, Inc. Website: http://www.heartware.com
HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
Press spacebar to pause and continue. Press esc to stop.